IE43768B1 - Oximes - Google Patents

Oximes

Info

Publication number
IE43768B1
IE43768B1 IE567/76A IE56776A IE43768B1 IE 43768 B1 IE43768 B1 IE 43768B1 IE 567/76 A IE567/76 A IE 567/76A IE 56776 A IE56776 A IE 56776A IE 43768 B1 IE43768 B1 IE 43768B1
Authority
IE
Ireland
Prior art keywords
formula
group
compound
oxime
pharmaceutically acceptable
Prior art date
Application number
IE567/76A
Other languages
English (en)
Other versions
IE43768L (en
Original Assignee
Duphar Int Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duphar Int Res filed Critical Duphar Int Res
Publication of IE43768L publication Critical patent/IE43768L/xx
Publication of IE43768B1 publication Critical patent/IE43768B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32Oximes
    • C07C251/50Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/58Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/04Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
    • C07C249/08Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reaction of hydroxylamines with carbonyl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IE567/76A 1975-03-20 1976-03-18 Oximes IE43768B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL7503310A NL7503310A (nl) 1975-03-20 1975-03-20 Verbindingen met antidepressieve werking.

Publications (2)

Publication Number Publication Date
IE43768L IE43768L (en) 1976-09-20
IE43768B1 true IE43768B1 (en) 1981-05-20

Family

ID=19823424

Family Applications (1)

Application Number Title Priority Date Filing Date
IE567/76A IE43768B1 (en) 1975-03-20 1976-03-18 Oximes

Country Status (27)

Country Link
US (1) US4085225A (en:Method)
JP (1) JPS6026776B2 (en:Method)
AR (2) AR211011A1 (en:Method)
AT (1) AT340895B (en:Method)
AU (1) AU505358B2 (en:Method)
BE (1) BE839744A (en:Method)
CA (1) CA1076142A (en:Method)
CH (4) CH626057A5 (en:Method)
DD (1) DD128332A5 (en:Method)
DE (1) DE2610886A1 (en:Method)
DK (1) DK144942C (en:Method)
ES (1) ES446192A1 (en:Method)
FI (1) FI61875C (en:Method)
FR (1) FR2304336A1 (en:Method)
GB (1) GB1535226A (en:Method)
GR (1) GR60052B (en:Method)
HU (1) HU171030B (en:Method)
IE (1) IE43768B1 (en:Method)
IL (1) IL49238A (en:Method)
IT (1) IT1063064B (en:Method)
MX (1) MX9203723A (en:Method)
NL (1) NL7503310A (en:Method)
PL (3) PL101951B1 (en:Method)
SE (1) SE410312B (en:Method)
SU (3) SU635867A3 (en:Method)
YU (1) YU39345B (en:Method)
ZA (1) ZA761434B (en:Method)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1110460B (it) * 1977-03-02 1985-12-23 Ciba Geigy Ag Prodotti che favoriscono la crescita delle piante e prodotti che proteggono le piante a base di eteri di ossime e di esteri di ossime loro preparazione e loro impiego
FR2639942B1 (fr) * 1988-12-02 1991-03-29 Sanofi Sa Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant
US5665756A (en) * 1994-08-03 1997-09-09 Hoechst Marion Roussel, Inc. Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
AU6776196A (en) * 1995-08-16 1997-03-12 Eli Lilly And Company Potentiation of serotonin response
IN182588B (en:Method) 1998-05-12 1999-05-08 Sun Pharmaceutical Ind Ltd
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
IN186677B (en:Method) 1999-11-12 2001-10-20 Sun Pharmaceutical Ind Ltd
WO2001078721A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
US20080021085A1 (en) * 2000-04-13 2008-01-24 Mayo Foundation For Medical Education And Research Method of reducing abeta42 and treating diseases
WO2001080845A2 (en) * 2000-04-24 2001-11-01 Aryx Therapeutics (2-aminoethyl) oxime derivatives for the treatment of depression
US7256191B2 (en) * 2000-04-24 2007-08-14 Aryx Therapeutics Materials and methods for the treatment of depression
CA2462903C (en) * 2001-10-12 2011-09-20 Serenix Pharmaceuticals, Llc Beta-lactamyl vasopressin v1a antagonists
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
ATE449633T1 (de) 2003-09-12 2009-12-15 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
ATE473967T1 (de) * 2003-11-26 2010-07-15 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
ES2515092T3 (es) 2003-12-11 2014-10-29 Sunovion Pharmaceuticals Inc. Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
US20050233010A1 (en) * 2004-04-19 2005-10-20 Satow Philip M Lithium combinations, and uses related thereto
WO2005108683A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CA2601709C (en) 2005-03-22 2017-02-14 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids
JP2008538573A (ja) 2005-04-22 2008-10-30 ワイス ベンゾフラニルアルカナミン誘導体およびその5−ht2cアゴニストとしての使用
AR056979A1 (es) * 2005-04-22 2007-11-07 Wyeth Corp Derivados de dihidrobenzofuranos y usos de los mismos
US20060252825A1 (en) * 2005-04-22 2006-11-09 Wyeth Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
US7402687B2 (en) 2005-04-22 2008-07-22 Wyeth Dihydrobenzofuran derivatives and uses thereof
CA2614289A1 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
PL1910346T3 (pl) * 2005-07-19 2019-09-30 Azevan Pharmaceuticals, Inc. Beta-laktamowy antagonista wazopresyny fenyloalaniny, cysteiny i seryny
NZ564789A (en) * 2005-07-22 2010-07-30 Myriad Genetics Inc High drug load formulations and dosage forms
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007231011A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
JP4615470B2 (ja) * 2006-03-29 2011-01-19 卓郎 簑和田 大脳の認知力を用いた疾患治療・予防の方法および医薬
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080167363A1 (en) * 2006-12-28 2008-07-10 Braincells, Inc Modulation of Neurogenesis By Melatoninergic Agents
EP2125017A2 (en) * 2007-01-11 2009-12-02 Braincells, Inc. Modulation of neurogenesis with use of modafinil
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
PT2491038T (pt) 2009-10-23 2016-07-14 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirrolos disubstituídos como modeladores de recetores de orexina
JP5815552B2 (ja) 2009-12-08 2015-11-17 ケース ウェスタン リザーブ ユニバーシティCase Westernreserve University 眼疾患を治療する化合物および方法
ES2858499T3 (es) 2010-07-01 2021-09-30 Azevan Pharmaceuticals Inc Compuestos para su uso en el tratamiento de trastorno explosivo intermitente
BR112013023810A2 (pt) 2011-03-17 2016-12-13 Lupin Ltd composições farmacêuticas de liberação controlada de inibidores seletivos da recaptação de serotonina
KR101427221B1 (ko) * 2012-08-29 2014-08-13 주식회사 에스텍파마 플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법
WO2014178064A2 (en) * 2013-04-03 2014-11-06 Zcl Chemicals Limited "an improved process for the preparation of fluvoxamine maleate"
CN106456578B (zh) 2014-02-07 2020-02-18 匈牙利科学院大学及其他机构附属研究所 Sigma-1受体激动剂化合物的用途
SG10202001065SA (en) 2014-03-28 2020-04-29 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases
MY197558A (en) 2016-03-10 2023-06-23 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
US12239125B2 (en) 2016-11-24 2025-03-04 SigmaDrugs Kutató Korlátolt Felelsség Társaság Compositions for organ preservation
EP3681871A4 (en) 2017-09-15 2021-05-26 Azevan Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF A BRAIN DAMAGE
KR20220049526A (ko) 2019-07-19 2022-04-21 바이오엑셀 테라퓨틱스 인코포레이티드 비-진정성 덱스메데토미딘 치료 양생법
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692835A (en) * 1967-04-05 1972-09-19 Jan Van Dijk Pharmacologically active amino-ethyl oximes

Also Published As

Publication number Publication date
CH629477A5 (de) 1982-04-30
MX9203723A (es) 1992-07-01
DK115976A (da) 1976-09-21
FI61875C (fi) 1982-10-11
PL100052B1 (pl) 1978-08-31
SU620206A3 (ru) 1978-08-15
CH629184A5 (de) 1982-04-15
IE43768L (en) 1976-09-20
SU635867A3 (ru) 1978-11-30
CH629761A5 (de) 1982-05-14
JPS51125345A (en) 1976-11-01
NL7503310A (nl) 1976-09-22
SE410312B (sv) 1979-10-08
AU505358B2 (en) 1979-11-15
ES446192A1 (es) 1977-10-01
IL49238A0 (en) 1976-05-31
HU171030B (hu) 1977-10-28
GB1535226A (en) 1978-12-13
ATA195476A (de) 1977-05-15
SE7603341L (sv) 1976-09-21
DE2610886C2 (en:Method) 1987-09-24
YU71476A (en) 1982-10-31
YU39345B (en) 1984-10-31
DD128332A5 (de) 1977-11-09
PL100614B1 (pl) 1978-10-31
SU645559A3 (ru) 1979-01-30
FI760699A7 (en:Method) 1976-09-21
DE2610886A1 (de) 1976-10-07
PL101951B1 (pl) 1979-02-28
JPS6026776B2 (ja) 1985-06-25
AR211153A1 (es) 1977-10-31
IT1063064B (it) 1985-02-11
GR60052B (en) 1978-04-04
BE839744A (fr) 1976-09-20
FR2304336B1 (en:Method) 1979-09-28
AT340895B (de) 1978-01-10
CA1076142A (en) 1980-04-22
AU1214776A (en) 1977-09-22
DK144942B (da) 1982-07-12
ZA761434B (en) 1977-10-26
US4085225A (en) 1978-04-18
IL49238A (en) 1978-08-31
AR211011A1 (es) 1977-10-14
FI61875B (fi) 1982-06-30
DK144942C (da) 1982-12-06
FR2304336A1 (fr) 1976-10-15
CH626057A5 (en:Method) 1981-10-30

Similar Documents

Publication Publication Date Title
IE43768B1 (en) Oximes
EP0170213B1 (en) Glutarimide antianxiety and antihypertensive agents
SK285165B6 (sk) Tetrahydropyridoétery, farmaceutický prostriedok s ich obsahom a ich použitie
US4575508A (en) 2-Substituted 1-(3'-aminoalkyl)-1,2,3,4-tetrahydro-β-carbolines, and their use as antiarrhythmic agents
JPS63295589A (ja) 生理活性物質k−252の誘導体
JPH03170481A (ja) 置換ピリミドベンズイミダゾール誘導体
RU2138501C1 (ru) Имидазопиридиназолидиноны, их соли и лекарственное средство
US4081551A (en) Oxime ethers having anti-depressive activity
HU182070B (en) Process for producing phenyl-piperazine derivatives
US4086361A (en) Aminoethyl oximes having anti-depressive activity
IE902788A1 (en) 2,3-Dihydro-1-(pyridinylamino)-indoles, a process for their preparation and their use as medicaments
EP0315112B1 (en) Novel amide compounds
HK24194A (en) Pyrrolo[1,2-a][4,1]benzoxazepines, process for their preparation, pharmaceutical compositions containing these compounds and therapeutical use
KR100382998B1 (ko) 6-메톡시-1h-벤조트리아졸-5-카르복사미드유도체,그제조방법및그것을함유하는의약조성물
US4060631A (en) Aminoethyl oxime ethers having anti-depressive activity
US4081552A (en) Oxime ethers having anti-depressive activity
US3262978A (en) O-arylamino-and-aralkyl-amino-alkylhydroxyl-amines
CN101307043A (zh) 6,8-二羟甲基白杨素和6,8-二羟甲基醚白杨素及其制备方法与药物用途
GB2100261A (en) Aminophenylalkylamine derivatives, a process for their preparation and their use as pharmaceuticals
HU184965B (en) Process for producing phenyl-piperazine derivatives of anti-agression activity
WO1997040046A1 (fr) Derives de benzoquinolizine et compositions medicinales
EP0084292A1 (en) N,N-disubstituted alkenamides and phenylalkenamides, processes for their production and their use as pharmaceuticals
FI74004C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara piperazinylpyrido/2,3-b/- och -/3,4-b/ pyrazinderivat.
JPS6342625B2 (en:Method)
JPH0533950B2 (en:Method)

Legal Events

Date Code Title Description
MK9A Patent expired